At the heart of the discipline sit synthetic genetic circuits, which the authors describe as the basic building blocks of the entire enterprise. These circuits control the production, turnover or depletion of specific DNA, RNA or protein molecules, giving researchers programmable control over gene expression and cellular behavior. The repertoire includes logic gates that mirror digital electronics, with BUFFER, NOT, AND, OR, XOR, NAND, NOR and XNOR configurations each activating or repressing output genes under distinct input conditions. Oscillators generate rhythmic fluctuations in protein concentrations, echoing natural circadian clocks and cell cycle regulators, while toggle switches act as biological memory, holding gene expression stably on or off much like flip-flop circuits in electronics. The landmark repressilator built by Elowitz and Leibler in Escherichia coli, a ring of three repressor proteins that suppress one another in sequence, produced green fluorescent protein oscillations with a period of roughly 150 minutes, about three times longer than the cell division cycle, demonstrating that entirely artificial networks could function robustly inside living bacteria.

The clinical implications of these circuits are already substantial. Genetic switches integrated into human cells can detect internal disease signals and respond with closed-loop logic, or react to external molecular cues in an open-loop configuration. When such circuits are built into next-generation chimeric antigen receptor T cells, they allow precise control over the timing and intensity of immune responses, improving both safety and effectiveness. A study by Daniels and colleagues designed more than 1,200 receptors combining twelve different signaling motifs and, using machine learning, identified synthetic motifs absent from natural receptors that created new T cell phenotypes with enhanced antitumor efficacy. In parallel, Li and colleagues developed synthetic zinc finger transcription factors, called synZiFTRs, that target an artificial 18-base-pair promoter not found in the human genome. Their activity could be controlled with three FDA-approved drugs: the antiviral grazoprevir induced anti-HER2 CAR expression in T cells, while tamoxifen triggered production of super high-affinity IL-2, producing drug-controllable antitumor effects in mouse models of NALM6 leukemia.

Synthetic chromosomes represent an even bolder frontier. Jason Chin’s team synthesized the entire E. coli genome, roughly four times larger than any previously synthesized genome, and compressed its genetic code from 64 to 61 codons by recoding 18,214 codon instances, using the REXER method to progressively replace the native genome with the synthetic version across eight parallel strains that were then combined by conjugation. In eukaryotes, the Sc2.0 Synthetic Yeast Genome Project, led by Jef Boeke of Johns Hopkins University, aims to build a designer genome for Saccharomyces cerevisiae, a organism with roughly 6,000 genes. Its signature SCRaMbLE system embeds more than 5,000 loxP recombination sites that can be rapidly activated to shuffle genetic content, generating millions of cell variants from which strains with improved industrial traits can be selected. After ten years of intensive work, an international collaboration spanning the UK, USA, China, Singapore, France and Australia completed synthetic chromosome XI, a 660,000-base-pair sequence that replaced a natural yeast chromosome while preserving normal cellular fitness through rigorous error correction.

Metabolic engineering, a discipline that emerged in the 1990s, is delivering some of the field’s most tangible products. Jay Keasling’s team engineered Saccharomyces cerevisiae to produce artemisinic acid, the precursor to the antimalarial drug artemisinin, by inserting and optimizing genes from multiple organisms including the malaria parasite Plasmodium falciparum, creating a sustainable fermentation route that sidesteps the variability of plant extraction. Lee and colleagues achieved something once thought impossible: engineered E. coli producing 1,4-butanediol, an industrial chemical made in more than 2.5 million tons annually that no living organism produces naturally, at a yield of 18 grams per liter from renewable sugars including glucose, xylose and sucrose. On the energy front, Nielsen and colleagues developed three microbial platforms, based on Saccharomyces cerevisiae, Zymomonas mobilis and E. coli, capable of fermenting lignocellulose sugars into bioethanol, though the authors note that competitive production will require optimization across every stage of the process. Dynamic metabolic control has also matured: by rewiring the transcriptional regulator FapR to balance malonyl-CoA supply and consumption in E. coli, researchers achieved a 15.7-fold improvement in fatty acid production.

The tools that make all of this possible have themselves undergone a quiet revolution. Standardized cloning remains foundational, with plasmids carrying replication origins, selection markers and promoters serving as the workhorses of gene transfer, and modular systems such as SureVector accelerating vector assembly. BioBrick standard parts, stored in the Standard Biological Parts Registry and central to the international iGEM competition, embody the field’s commitment to abstraction and interchangeability. Gibson assembly allows multiple DNA fragments with homologous overlapping ends to be joined seamlessly in an hour or less without restriction enzymes, while Golden Gate assembly and its extensions, including MoClo and Golden Braid, use type IIS enzymes to combine many fragments in a single tube. De novo DNA synthesis now delivers designed sequences within days or weeks, though cost and accuracy remain limiting factors. Perhaps most conceptually important is the chassis: researchers at the J. Craig Venter Institute, starting from Mycoplasma genitalium, progressively defined a minimal cell, and by 2016 produced a organism with just 473 genes across 531 kilobase pairs, a simplified biological platform that minimizes interference with engineered circuits.

Beyond cancer, the review documents synthetic biology’s reach into diagnostics, tissue engineering and drug delivery. Engineered E. coli that produce LacZ upon contacting tumor cells can detect tumors smaller than one centimeter through a simple urine luminescence test, while Salmonella enterica colonizing tumor tissue can convert a prodrug into 5-fluorouracil that eradicates cancer cells. In tissue engineering, synthetic circuits built on Tet-on and Tet-off systems allow temporally controlled expression of genes such as Runx2 and Sox9, guiding bone and cartilage formation in implanted scaffolds, and biomaterial-encased gene switches have sustained reporter expression for more than 300 days in some systems. Bottom-up synthetic cells are emerging as drug carriers: Chen and colleagues built synthetic beta cells from multi-compartment vesicles containing glucose oxidase, catalase and insulin-loaded liposomes that released insulin in response to glucose and normalized blood sugar in type 1 diabetic mice, while other synthetic cells producing Pseudomonas exotoxin A killed cancer cells more effectively than purified toxin alone.

Biosensors and anti-infective therapies round out the medical portfolio. The ROSALIND platform developed by Collins and colleagues uses cell-free, freeze-dried reactions with allosteric transcription factors to detect 16 different water contaminants, producing visible RNA-based signals that can be shipped at ambient temperature and deployed in field tests on municipal water. Against antibiotic resistance, engineered phages have shown striking results: a T7 phage producing the biofilm-degrading enzyme dispersin B eliminated 99.997 percent of bacteria within a biofilm, and a lytic M13 phage suppressing bacterial DNA damage responses significantly enhanced the killing of resistant cells by existing antibiotics. Phage display technology, pioneered by George Smith and applied to antibodies by Gregory Winter, underlies drugs such as adalimumab for rheumatoid arthritis, and AI tools like AlphaFold are now accelerating therapeutic antibody design by modeling binding sites with unprecedented speed and accuracy.

Agriculture and industry complete the picture, alongside sobering warnings. Pivot Bio’s engineered nitrogen-fixing bacteria increased corn yields by 5.8 bushels per acre while cutting chemical fertilizer use by 25 pounds per acre, without the greenhouse gas emissions and runoff of conventional fertilizers. CRISPR/Cas9 editing has boosted GABA content in tomatoes seven- to fifteen-fold, raised lycopene levels 5.1-fold through multiplex editing, and enabled de novo domestication of allotetraploid wild rice by Jiayang Li’s team. Even de-extinction has entered the agenda, with George Church’s project aiming to modify around 45 genes in the Asian elephant genome to create a cold-tolerant, mammoth-like hybrid. Yet the authors close with a caution: the same tools that promise sustainable fuels and personalized medicines could, through accident or intent, produce harmful biological agents, and they argue that strong biosafety and biosecurity policies at national and global levels are a critical precondition for safely delivering synthetic biology’s benefits to society. By 2030, they predict, most people will use a product built by this technology, whether they know it or not.

Subject of Research: Applications of synthetic biology in medicine, agriculture and industry

Article Title: Synthetic biology and application areas

Article References: Karataş, P., & Ayaz, F. (2025). Synthetic biology and application areas. Discover Biotechnology, 2(1), Article 3. https://doi.org/10.1007/s44340-025-00010-5

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00010-5

Keywords: synthetic biology, genetic circuits, CAR-T cell therapy, synthetic chromosomes, metabolic engineering, CRISPR, biosensors, drug delivery, biofuels, Sc2.0 yeast genome, repressilator, biosecurity

The research, led by Yutong Cai and Zhaoyue Zhong, with Zefeng Zhang, Bo-Wei Qin and senior author Wei Lin at Fudan University in Shanghai, introduces a rigorous mathematical treatment of what the authors call modulatability. Rather than asking how to push an oscillator toward a target behavior through trial and error, the team asked a more fundamental question about the geometry of the problem itself. If you want to impose several properties on an oscillating system at once, say a specific frequency, a specific amplitude, and a specific phase relationship across parts of a network, how many adjustable knobs do you need? Their central theoretical result is strikingly elegant: the local uniqueness of a solution is generally guaranteed when the number of free parameters equals the number of properties being targeted. Too few knobs and the problem is overconstrained, with most target combinations simply unreachable. Too many and solutions proliferate, making it hard to know which one a solver will find.

This dimensional matching principle may sound abstract, but it has immediate practical consequences. In the biological sciences, researchers routinely try to reprogram oscillators whose dynamics involve dozens of interacting variables. Synthetic biologists, for example, have spent two decades engineering genetic circuits such as the repressilator, a ring of three genes that repress one another in turn and thereby generate oscillating protein concentrations. Tuning such circuits to display both a desired period and a desired amplitude simultaneously has historically required laborious computational redesign or experimental screening. The Fudan team’s framework reframes the whole enterprise: instead of simulating trajectories forward and hoping to stumble on good parameters, the modulation task is treated as a property-based inverse problem, in which the desired properties are fixed and the equations are solved backward for the parameters that produce them.

The technical machinery behind the framework combines several ideas from dynamical systems and numerical analysis. The oscillatory trajectories of the system are represented through a Fourier expansion, allowing periodic solutions to be described by a finite set of coefficients once a truncation order is chosen. The desired properties, such as minima of particular protein activities or the period of the collective rhythm, are expressed as functions of these coefficients and of the system’s kinetic parameters. Solving for the parameters then becomes a root-finding problem in a space whose dimension is chosen deliberately to match the number of targets. The authors deploy Newton-type iterations to converge on solutions, and they use continuation strategies, stepping gradually through parameter space, to follow modulation paths even when the targets are far from the system’s natural behavior. Sweeps over system dimension, Fourier truncation order, number of targets, iteration tolerance, and continuation steps, reported in the paper’s extended data, map out how computational cost scales with each factor.

Crucially, the framework is not merely a simulation exercise. The team validated it on electronic analogs of genetic circuits, building hardware implementations of the repressilator concept in which voltages play the role of protein concentrations. From recorded voltage time courses alone, the researchers inferred the underlying parameters of the oscillating circuit and then modulated them to hit orthogonal targets, meaning goals that do not interfere with one another, such as independently shifting the period while holding amplitude fixed. The experiments included orthogonal period modulation tasks with two and with three simultaneous targets, and the inferred parameter distributions were tight and unimodal, suggesting that the inverse problem is well-posed in precisely the sense the theory predicts. This hardware demonstration matters because electronic circuits are a standard proving ground for ideas intended eventually for living cells, capturing the nonlinear feedback structure of genetic networks while remaining far easier to measure and perturb.

The data-driven side of the work is where the framework arguably delivers its most compelling numbers. In benchmark comparisons against baseline inference methods, the property-based approach achieved shorter runtimes and higher accuracy, a combination that is rare in inverse problems, where speed is usually bought at the cost of precision. The authors also demonstrated the framework on a model of an engineered Sir2-HAP negative feedback loop, a genetic oscillator linked to cellular longevity in yeast. In that system, low activity of the SIR2 and HAP proteins corresponds to a detrimental aging zone that the oscillating state variables pass through. By identifying a parameter set that up-regulates the minimal activities of both proteins, the framework showed in stochastic simulations, which added Ornstein-Uhlenbeck noise to eight kinetic terms, that the modulated oscillator avoids the aging zone more effectively, with distributions of minimum protein levels shifted upward across one hundred independent runs. It is a concrete illustration of how abstract parameter identification could translate into a design principle for extending cellular lifespan.

Networks add another layer of complexity, and the paper addresses it head-on. In one extended demonstration, the team applied their method to a FitzHugh-Nagumo neuronal network of one hundred nodes arranged on a randomly generated Barabasi-Albert topology, a structure mimicking the heterogeneous, hub-rich connectivity seen in many real systems. With fifty target nodes whose amplitudes needed adjustment, the researchers modulated random subsets of edges and measured how often the modulation succeeded while the network remained oscillatory. The results, summarized across many repeated trials, revealed how success rates depend on the balance between the number of targeted nodes and the number of edges available for modulation, with the equal-dimension condition again emerging as the natural dividing line. For anyone trying to control synchronization patterns in power grids, neural tissue, or coupled laser arrays, this kind of systematic map of when control is feasible is exactly the missing piece.

What makes the study resonate beyond applied mathematics is the sheer breadth of oscillatory phenomena it touches. The references span circadian medicine, the bioelectrical phase transition that patterns the first vertebrate heartbeats, collective oscillations emerging in massive human crowds, amplitude and frequency modulation of subthalamic beta oscillations in Parkinson’s disease, and synthetic oscillators designed to slow cellular aging. In each of these domains, the practical question is the same: which properties of the rhythm can be moved, and by touching which parameters? The modulatability framework offers a principled answer, replacing intuition with a dimension-counting criterion and replacing forward simulation with inverse problem solving. It also connects to a broader theoretical conversation about controlling complex networks, complementing earlier work on controllability, functional control of oscillator networks, and inverse problems for dynamic patterns in coupled systems.

The authors have made their work unusually accessible. The source code is publicly available on GitHub, with a frozen release archived on Zenodo, and a figure-to-script mapping document allows readers to reproduce individual results directly. Source data, including network topologies, modulation parameters, oscillatory trajectories, stochastic realizations, and the experimental voltage recordings from the electronic circuit, are deposited without restrictions. For a field where reproducibility of nonlinear dynamics can be notoriously difficult, this level of transparency lowers the barrier for other groups to test the framework on their own oscillators, whether biological, neural, mechanical, or photonic.

The larger significance of the work lies in its reframing. For years, the modulation of oscillators has been pursued through two parallel traditions, one statistical and one rooted in dynamical systems theory, each producing partial answers. By proving a general condition for when modulation parameters exist uniquely and packaging the insight into an efficient computational pipeline, the Fudan team has given both theorists and experimentalists a common language for a problem that cuts across biology, neuroscience, and engineering. If rhythms govern health, and disrupted oscillations are implicated in conditions from diabetes to psychiatric illness, then knowing exactly when and how a rhythm can be retuned is more than a mathematical curiosity. It is a step toward making oscillators, whether in a cell, a circuit board, or a brain, into things we can genuinely engineer.

Subject of Research: Mathematical theory and computational framework for the modulatability of complex oscillators

Article Title: Modulatability of complex oscillators

Article References: Modulatability of complex oscillators. (n.d.). https://doi.org/10.1038/s43588-026-01050-5

Image Credits: AI Generated

DOI: 10.1038/s43588-026-01050-5

Keywords: oscillators, dynamical systems, inverse problems, complex networks, synchronization, genetic circuits, repressilator, circadian rhythms, parameter identification, nonlinear dynamics, Nature Computational Science, synthetic biology